#Israel #Medical Device #Yokneam #BPH Treatment #Butterfly Medical

Butterfly Medical Secures $21 Million in Series C Funding

In a major development for men affected by benign prostatic hyperplasia (BPH), Butterfly Medical has successfully completed its Series C funding round, raising an impressive $21 million. This significant financial boost highlights strong institutional interest and validates the company's innovative approach to treating this common condition. With participation from a variety of investors, including the European Innovation Council (EIC), Junson Capital, MedVenture, and New Rhein Healthcare Investors, the funding is expected to propel Butterfly Medical's proprietary non-surgical solution into the spotlight.

Patrick MacCarthy, the CEO of Butterfly Medical, expressed enthusiasm about the funding's implications. He stated that the round exceeded their initial target and underscored the clinical potential of the Butterfly prostatic retraction device. As the company moves forward, it aims to finalize its pivotal trial and escalate its focus on commercialization efforts in collaboration with the FDA. This newly acquired capital will be instrumental in navigating regulatory processes and facilitating wider access to their groundbreaking technology.

The Butterfly prostatic retraction device is designed to offer a minimally invasive solution for men suffering from BPH—a condition that affects a significant number of men worldwide. By mechanically retracting the lateral lobes of the prostate, the device aims to restore natural urine flow without the need for cutting, burning, or removing tissue. This innovative approach not only alleviates debilitating symptoms but also ensures that the procedure is fully reversible, offering patients a compelling alternative to traditional surgical options.

The device has already received CE Mark approval in Europe, allowing for limited clinical applications. Butterfly Medical will showcase its technology at the American Urological Association (AUA) 2026 Annual Meeting, scheduled for May 15-18 in Washington, D.C. Attendees can engage with the Butterfly Medical team at Booth #448, where they will share the latest developments regarding the device and its clinical significance.

“Achieving a funding milestone similar to our competitors but with less than half the capital underscores the quality and efficiency of our development efforts,” remarked Nayan Parekh, PhD, Managing Partner at New Rhein Healthcare Investors. He expressed excitement over the device’s clinical data and potential for significant market adoption. With a focus on ease of use, competitive manufacturing costs, and avoidance of durable capital equipment, Butterfly Medical stands poised for success in the burgeoning market for BPH treatments.

Butterfly Medical’s commitment to redefining the standard of care for BPH treatment could significantly improve the quality of life for millions of affected men globally. Their innovative non-surgical solution presents a long-needed alternative to conventional therapies, addressing the needs of patients who seek effective and less invasive treatment options.

For more details about Butterfly Medical and its groundbreaking solutions, visit their official website or follow them on LinkedIn for updates. As we look ahead, the potential for their technology to reshape BPH treatment is emerging as a compelling narrative in the medical device landscape.